Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus

Authors: He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M
Publication: Clin Pharmacokinet
Keywords: Adamantane, administration, administration & dosage, adult, adverse effects, aged, analogs & derivatives, area under curve, blood, Blood Glucose, chemically induced, cross-over studies, diabetes mellitus, Dose-Response Relationship, Doubl, drug, oral, type 2
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus.

The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process

The Application of Systematic Analysis for Identifying and Addressing the Needs of the Pharmacometric Process

Authors: Grasela TH
Conference: PAGE
Keywords: communications, data assembly, dataset creation, dataset requirements, enterprise engineering, forensic pharmacometrics, gap analysis, informatics, PKPD methodology, process, team
Division: Clinical Pharmacology and Pharmacometrics (CPP)

The current implementation of a pharmacometric process has, in most cases, grown from the ad hoc application of modeling and simulation activities to the drug-development process. This ad hoc…

Mechanism-Based Pharmacokinetic / Pharmacodynamic Model for Hepatoprotective Effect of Dexamethasone on Transient Transaminitis After Trabectedin (ET-743, Yondelis®) Treatment

Mechanism-Based Pharmacokinetic / Pharmacodynamic Model for Hepatoprotective Effect of Dexamethasone on Transient Transaminitis After Trabectedin (ET-743, Yondelis®) Treatment

Authors: Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez Ruixo JJ
Conference: ASCO
Keywords: ALT, antineoplastics, cancer, dose reduction, heptocyte, indirect response model, intravenous, IV, liver, mixture model, Oncology, PK/PD, precursor-dependent model, safety, simulation, time course
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Reversible transient elevations in transaminases have been observed after trabectedin (T) administration, despite no alteration in plasma PK. A PKPD model was developed to evaluate the time course of ALT elevation…

Population pharmacokinetics of tigecycline in healthy volunteers

Population pharmacokinetics of tigecycline in healthy volunteers

Authors: Van Wart S, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS
Publication: J Clin Pharmacol
Keywords: adolescent, adult, aged, analogs & derivatives, anti-bacterial agents, area under curve, biological, blood, clinical trials, drug administration schedule, female, humans, male, middle-aged, Minocycline, models, multicenter studies, Phase I as Topic
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Tigecycline, a novel glycylcycline, possesses broad-spectrum antimicrobial activity. A structural population pharmacokinetic model for tigecycline...

The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools

The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools

Authors: De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ
Publication: Drug Metab Dispos
Keywords: bioavailability, hepatic blood clearance, oral bioavailability, pharmacokinetics, physiologically based prediction, rat
Software: ADMET Predictor®, GastroPlus®

The aim of this study was to assess a physiologically based modeling approach for predicting drug metabolism, tissue distribution, and bioavailability in rat for a structurally diverse set of...

Population pharmacokinetic model for gatifloxacin in pediatric patients

Population pharmacokinetic model for gatifloxacin in pediatric patients

Authors: Rubino CM, Capparelli EV, Bradley JS, Blumer JL, Kearns GL, Reed M, Jacobs RF, Cirincione B, Grasela DM
Publication: Antimicrob Agents Chemother
Keywords: administration, adult, adverse effects, aged, analysis, biological, blood, body weight, child, clinical trials, Clinical Trials as Topic, computer simulation, fluoroquinolones, humans, infant, infection, models, oral, preschool, statistical
Division: Clinical Pharmacology and Pharmacometrics (CPP)

The broad spectrum of antimicrobial activity, oral bioavailability, extensive tissue distribution, and once-daily intravenous or oral dosing of gatifloxacin...

Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling

Effect of Lifestyle Intervention on the Placebo Response in Anti-Obesity Trials: Considerations for Exposure-Response Modeling

Authors: Cirincione B, Passarell JA, Cummings M, Ludwig E, Grasela TH, Halseth A, Fineman MS
Conference: ASCPT
Keywords: anti-obesity, BMI, body mass index, Endocrinology, lifestyle intervention, obese, PK/PD, PKPD methodology, placebo, time course, time-dependent, weight, weight loss
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Successful clinical development of anti-obesity agents is aided by characterization of the placebo effect, which can be significant when lifestyle intervention (LSI) accompanies pharmacologic therapy.

Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide

Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide

Authors: Fineman MS, Phillips L, Jaworowicz DJ, Cirincione B, Ludwig E, Taylor K, Kothare PA, Baron A, Grasela TH
Conference: ASCPT
Keywords: antibody, antidiabetic, antidiabetic agents, dose selection, drug development process, Endocrinology, exendin, exposure-response, fixed dosing, gender, geometric mean ratio, glucose, hormones, learn-confirm, NONMEM, PK, PK/PD, titer, weight
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Population pharmacokinetic (PK) and pharmacodynamic (PK/PD) models based on early Phases 1 and 2 data for the new antidiabetic medication exenatide (ex) supported transition from weight-based to…

Population Pharmacokinetics of Paliperidone ER in Healthy Subjects and Patients With Schizophrenia

Population Pharmacokinetics of Paliperidone ER in Healthy Subjects and Patients With Schizophrenia

Authors: Cirincione B, Redman M, Fiedler-Kelly J, Ludwig E, Vermeulen A
Conference: ASCPT
Keywords: antipsychotic, CrCL, creatinine clearance, extended release, intravenous, IV, lag time, LBM, lean body mass, NONMEM, oral, OROS, phenotype, PK, psychiatry, psychotherapeutic agents
Division: Clinical Pharmacology and Pharmacometrics (CPP)

To develop a population pharmacokinetic (PPK) model for paliperidone extended-release (ER) and to evaluate the influence of selected covariates.

Informatics: the fuel for pharmacometric analysis

Informatics: the fuel for pharmacometric analysis

Authors: Grasela TH, Fiedler-Kelly J, Cirincione B, Hitchcock D, Reitz K, Sardella S, Smith B
Publication: AAPS J
Keywords: analysis, data assembly, data_assembly_and_programming, decision-making, forensic pharmacometrics, informatics, methods, models, pharmaceutical, pharmacokinetics, Technology, Theoretical
Division: Clinical Pharmacology and Pharmacometrics (CPP)

The current informal practice of pharmacometrics as a combination art and science makes it hard to appreciate the role that informatics can and should...